In Reply: Neoadjuvant TKI Study in Early- and Intermediate Stage Hepatocellular Carcinoma

This letter to the editor responds to comments from Rizzo et al on recently reported results of a phase II study of dovitinib therapy for hepatocellular carcinoma.

Automated summary

This letter to the editor responds to comments made by Rizzo et al on the recently reported phase II study results of dovitinib therapy for hepatocellular carcinoma.